DMRA Damora Therapeutics, Inc.

NASDAQ
$20.66

Damora Therapeutics, Inc. (DMRA) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.52 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -30.9% since its last earnings release on August 10, 2026.

Damora Therapeutics Missed Consensus Estimates
Monday, August 10, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 4:05 PM ET
Earnings Whisper
-
vs ($0.52)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $26.13

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Damora Therapeutics, Inc.

Galecto Inc. is a clinical stage biotechnology company with advanced programs in fibrosis and cancer centered on galectin-3 and LOXL2. The Company's pipeline includes an inhaled galectin-3 modulator currently in Phase 2b for the potential treatment of idiopathic pulmonary fibrosis. Galecto Inc. is headquarters in Copenhagen, Denmark.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.